Long COVID Treatment 2026: The Complete Evidence Guide
By OneDayMD Editorial Team · Published September 30, 2026 · Updated October 2026
.png)
Quick Answer: does anything work for Long COVID?
No specific treatment has been proven to work for Long COVID in general. Randomized trials have found no benefit from extended Paxlovid (959 adults), metformin (396) or short-course hyperbaric oxygen (80). Promising but unconfirmed signals include the SIM01 synbiotic (463 people, Hong Kong) and physical-activity coaching (50). For prevention during acute COVID, Paxlovid (144 people) and metformin show mixed or underpowered results. Care remains individualized and symptom-focused.
- Re-checked every trial against primary sources and corrected details (for example, PANORAMIC Norway: 144 enrolled, 143 followed up).
- Added STOP-PASC and PAX LC to the Paxlovid evidence, COVID-OUT to prevention, and the 24-week STIMULATE-ICP result.
- Added trial limits that were missing (SIM01 single centre; fasting attrition; metformin placebo recovery).
- Updated low-dose naltrexone to the 2026 BMJ Open review; added company-reported ADDRESS-LC topline data.
- Fixed table-of-contents links; added a CEBM key, FAQ and AI-assistant guide.
Table of Contents
- Quick Answer
- How evidence is graded here (CEBM)
- What is Long COVID?
- Evidence grid: every trial at a glance
- Treating established Long COVID
- — Does Paxlovid work?
- — Does the SIM01 synbiotic work?
- — Does intermittent fasting work?
- — Does metformin treat it?
- — Rehabilitation, digital care and activity coaching
- — Does hyperbaric oxygen work?
- — What is new since publication?
- Can anything prevent Long COVID?
- Supplements, nattokinase and low-dose naltrexone
- Bottom line: supported vs experimental
- How to read a treatment claim
- What should patients do with this evidence?
- Using this article with Claude, ChatGPT, Gemini and Perplexity
- Frequently asked questions
- Sources and further reading
How is the evidence graded in this article?
We label each study with its Oxford CEBM (OCEBM 2011) level for treatment questions: L1 systematic review of randomized trials; L2 individual randomized trial; L3 non-randomized controlled cohort; L4 case series or uncontrolled before–after study; L5 mechanistic reasoning. The level describes study design, not whether the result was positive. Size, blinding, endpoint choice, attrition and replication determine how much weight a result deserves, so each entry also carries a certainty note.
What is Long COVID, and how is it diagnosed?
Long COVID, also called post-COVID condition or post-acute sequelae of SARS-CoV-2 infection (PASC), means persistent or recurrent symptoms after COVID-19: commonly fatigue, post-exertional symptom exacerbation (PESE), cognitive problems, breathlessness, sleep disturbance, dysautonomia and pain. The CDC states that no laboratory test can definitively diagnose or rule out Long COVID; diagnosis relies on history, examination and targeted testing to exclude other causes (CDC clinical guidance).
Two points shape how to read every trial below. First, Long COVID is heterogeneous, so a treatment can help one subgroup without helping everyone. Second, prevention (acting during acute COVID) and treatment (acting months later) are separate questions; a prevention signal does not show that a drug treats established disease.
Evidence grid: how strong is the randomized evidence for each Long COVID treatment?
Strong enough to rule out several popular ideas; not strong enough to recommend one general protocol. A 2026 systematic review of 43 randomized trials (2,878 participants) rated certainty as low in all but one study; its searches ended in August 2024, so it predates RECOVER-VITAL, STIMULATE-ICP and the 2026 metformin trial (Tamariz et al.).
| Intervention | Key trial | Design and size | Main finding | CEBM level / certainty |
|---|---|---|---|---|
| Paxlovid, established Long COVID | RECOVER-VITAL, Lancet Infect Dis 2026 | Phase 2, double-blind, placebo-controlled; 959 adults; 69 US sites | No benefit at 15 or 25 days in any of three phenotypes | L2: large, negative |
| SIM01 synbiotic | Lau et al., Lancet Infect Dis 2024 | Double-blind RCT; 463 adults; one Hong Kong centre | More participants had alleviation of five symptoms at 6 months | L2: promising; needs replication |
| Intermittent fasting + no-added-sugar diet | Bunker et al., Sci Rep 2025 | Open-label crossover; 77 started, 58 completed | Larger symptom drop in fasting weeks; frequent flare-ups | L2: preliminary; high bias risk |
| Metformin or UDCA, established | Lim et al., Ann Intern Med 2026 | Double-blind RCT; 396 adults; 14 days | Recovery 63.6% / 68.2% / 68.2% (metformin / UDCA / placebo) | L2: negative |
| MRI-guided care; digital rehabilitation | STIMULATE-ICP, Nat Med 2026 | Cluster-randomized phase 3; 1,152 participants | No added benefit at 12 weeks; small digital-rehab gains at 24 weeks (secondary) | L2: mixed |
| Hyperbaric oxygen (10 sessions) | HOT-LoCO, BMJ Open 2025 | Double-blind, sham-controlled; 80 participants | No difference from sham on primary endpoints | L2: negative, small |
| Physical-activity coaching | Diciolla et al., Sci Rep 2026 | Assessor-blinded pilot; 50 participants | Feasible; better activity, walking and fatigue vs usual care | L2: pilot only |
| Paxlovid, prevention | PANORAMIC Norway, Lancet Infect Dis 2026 | Double-blind; 144 enrolled of 2,000 planned | Long COVID at 3 months: 26% vs 43% (RR 0.60) | L2: underpowered |
| Metformin, prevention | COVID-OUT 2023; ACTIV-6 | Double-blind RCTs in outpatients | COVID-OUT: HR 0.59 (secondary). ACTIV-6: primary endpoint missed threshold | L2: mixed |
| Low-dose naltrexone | BMJ Open 2026 systematic review | No RCTs; four small before–after studies | Possible benefit; low certainty | L4: uncontrolled |
| Nattokinase | 2026 candidate-treatment review; mechanistic and broader cardiovascular literature | No human Long COVID studies demonstrating benefit identified in the cited 2026 review | Fibrinolytic activity is not proof of Long COVID treatment efficacy | L4: uncontrolled |
| Bezisterim (ADDRESS-LC) | Company topline, Sept 2026 | Phase 2, double-blind; 203 participants | No significant effect on 22 endpoints overall; subgroup signal | Not peer reviewed |
| Curcumin with quercetin | Khan et al., Pharmaceuticals 2026 | Open-label, single-arm exploratory study; 15 enrolled, 14 completed; 8 weeks | Symptom scores improved from baseline; no control group, so treatment effect is uncertain | L4: uncontrolled |
| Nattokinase + bromelain + curcumin | Hulscher et al., 2023 proposed protocol | Mechanistic proposal; no confirmatory randomized trial establishing the combination's benefit | Not a validated spike-protein detoxification or microclot treatment protocol | L4: uncontrolled |
Swipe sideways on mobile to see all columns.
Which treatments have been tested in established Long COVID?
The sections below cover people who already have persistent symptoms. Each opens with the direct answer.
Does Paxlovid (nirmatrelvir–ritonavir) work for established Long COVID?
No. Extended Paxlovid did not improve established Long COVID in RECOVER-VITAL, the largest antiviral trial so far. Baden et al. (Lancet Infect Dis 2026) enrolled 959 adults at 69 US sites between July 2023 and early 2025. Participants were grouped by cognitive, autonomic or exercise-related (post-exertional) phenotype and randomized to 25 days of Paxlovid, 15 days of Paxlovid followed by ritonavir plus placebo, or 25 days of ritonavir plus placebo. The primary endpoint was a clinically meaningful change in patient-reported outcomes at day 90; the authors concluded there was no evidence of benefit in any of the three phenotypes (RECOVER summary).
Two earlier randomized trials agree: STOP-PASC (155 participants, 15 days; JAMA Intern Med 2024) showed no overall treatment effect, and PAX LC (Lancet Infect Dis 2025) found no significant improvement at day 28. These results do not rule out viral persistence in some patients; they show that these regimens did not produce clinical improvement in the populations tested.
Does the SIM01 synbiotic work for Long COVID symptoms?
It helped more participants than placebo in one well-run trial, but it needs replication. In Lau et al. (Lancet Infect Dis 2024), 463 adults in Hong Kong with at least one of 14 post-acute COVID symptoms for four or more weeks were randomized (232 SIM01, 231 placebo) to sachets of 10 billion colony-forming units twice daily for six months. The primary outcome was symptom alleviation at six months. Adverse events were similar between groups.
| Symptom alleviated at 6 months | SIM01 vs placebo (%) | Odds ratio |
|---|---|---|
| Fatigue | 62.8 vs 42.6 | 2.27 |
| Memory loss | 42.0 vs 26.9 | 1.97 |
| Difficulty concentrating | 62.3 vs 38.5 | 2.64 |
| Gastrointestinal / digestive upset | 70.2 vs 54.1 | 1.99 |
| General unwellness | 77.3 vs 59.0 | 2.36 |
Percentages from the trial's 2023 conference abstract.
Limits: a single centre, an all-Chinese study population and a vitamin C placebo. The result belongs to this standardized formulation and should not be generalized to other probiotics, fermented foods or generic microbiome supplements. SIM01 does not show that gut dysbiosis causes Long COVID.
Does intermittent fasting treat Long COVID?
It is a preliminary signal, not a prescription. Bunker et al. (Sci Rep 2025) ran a 10-week open-label crossover trial: after a two-week run-in, participants did four weeks of a no-added-sugar diet with a 10–12 hour eating window (TRE) and four weeks of the same diet with 16:8 fasting plus a weekly water-only fast (median 38 hours). Of 77 who started, 58 (75%) completed and formed the analytic sample. Symptom score fell 10.2 points during fasting vs 2.8 during TRE (p=0.008); symptom count fell 5.0 vs 1.4 (p=0.002). Over all 10 weeks, mean score fell from 37.8 to 18.2.
Limits: no blinding, patient-reported outcomes, no washout, no follow-up after the intervention, enrollment stopped early, and a patient-led, all-volunteer team. Participants with diabetes, pregnancy or an eating-disorder history were excluded. The mechanisms discussed (autophagy, viral clearance) remain hypotheses.
Does metformin treat established post-COVID condition?
No, not in a 2-week course. Lim et al. (Ann Intern Med 2026) randomized 396 adults at two South Korean hospitals (median age 36; 72% women) to metformin (up to 1,500 mg/day), ursodeoxycholic acid (900 mg/day) or placebo for 14 days. Recovery at 8 weeks (PASC index score below 12) was 63.6% with metformin, 68.2% with UDCA and 68.2% with placebo. The high placebo recovery rate shows why uncontrolled improvement after a treatment proves little. Longer courses, other populations and other doses were not tested.
Do rehabilitation, digital care or activity coaching help?
Specialist care helps many people; the specific add-ons tested did not clearly add more at 12 weeks. STIMULATE-ICP (Nat Med 2026) cluster-randomized 1,152 participants across six NHS clinics to usual care, multi-organ MRI, digital rehabilitation, or both. Fatigue improved in all arms, with no significant extra benefit from MRI or digital rehabilitation on the 12-week primary outcome. Digital rehabilitation showed small but statistically significant gains in fatigue and quality of life at 24 weeks, a secondary result (UCL summary). Because all arms improved and none was untreated, natural recovery and clinic care cannot be separated.
Physical-activity coaching showed an encouraging pilot signal. In Diciolla et al. (Sci Rep 2026), 50 people recruited from one patient advocacy group received a 12-week remote coaching programme (weekly sessions, activity tracker, goal setting) or usual care. The primary outcome was feasibility, which was met (89% recruitment, 92% retention, no intervention-related adverse events). At three months coaching improved steps, sedentary time, walking distance, dyspnoea and fatigue; anxiety and depression did not change. Limits: small pilot, baseline imbalances, unblinded participants, and a usual-care group that also wore trackers.
Why pacing matters. Some patients experience PESE, with symptoms worsening hours to days after physical or mental exertion. Rehabilitation should be individualized and symptom-guided rather than a generic "exercise more" prescription; see the CDC clinical guidance and WHO post-COVID-19 condition resources.
Does hyperbaric oxygen therapy work for Long COVID?
Evidence is insufficient for routine use. In HOT-LoCO (Kjellberg et al., BMJ Open 2025), 80 previously healthy adults aged 18–60 were randomized to 10 hyperbaric oxygen sessions or sham over six weeks; the primary endpoint analysis (79 participants) showed no more short-term benefit than sham. An earlier sham-controlled trial using a different protocol reported benefits (Hadanny et al., Sci Rep 2024 follow-up), so the question is protocol-specific and unsettled. This result does not exclude benefit in every subgroup.
What new Long COVID trial results appeared in September 2026?
Company-reported topline data for bezisterim; no peer-reviewed result yet. BioVie announced on September 15, 2026 that its phase 2 ADDRESS-LC trial (203 participants, randomized, double-blind, placebo-controlled, exploratory) did not reach significance on any of 22 endpoints in the full population, with a reported benefit in a subgroup with more severe baseline fatigue, post-exertional malaise and cognitive impairment (company release; The Sick Times). The company notes the FDA has not validated these endpoints as surrogate endpoints. Treat it as hypothesis-generating until peer-reviewed data and a confirmatory trial exist.
Separately, a brain-imaging study reported September 21, 2026 suggested dopamine-neuron involvement in Long COVID (CAMH summary). That is a mechanistic finding, not a treatment trial.
Can anything prevent Long COVID after acute COVID-19?
Possibly, but nothing is proven. Three randomized datasets point in different directions.
| Trial | Intervention and population | Result | Interpretation |
|---|---|---|---|
| PANORAMIC Norway (Lancet Infect Dis 2026) | Paxlovid vs placebo during acute COVID; 144 enrolled (66/78), 2,000 planned | At 3 months, Long COVID in 17 of 66 (26%) vs 33 of 77 (43%); RR 0.60 (95% CI 0.37–0.98) after imputing one missing value | Positive signal, but stopped early; authors say limited size precludes firm conclusions |
| COVID-OUT (Lancet Infect Dis 2023) | Metformin in outpatient adults with overweight or obesity | Cumulative incidence by day 300: 6.3% vs 10.4%; HR 0.59 (0.39–0.89). Ivermectin and fluvoxamine showed no effect | Long COVID was a secondary outcome added during the trial; the primary endpoint was severe COVID by day 14 |
| ACTIV-6 metformin | Metformin up to 1,500 mg/day for 14 days; about 3,000 low-risk outpatients | Primary endpoint (symptoms at day 180): risk ratio 0.79 (95% CrI 0.47–1.23), below the efficacy threshold. Clinician-diagnosed Long COVID (secondary): 0.56% vs 1.17% | Event rates were low; secondary signals support further study, not a conclusion |
Protocol for PANORAMIC Norway: PMC12590622.
Evidence lesson: a secondary or exploratory result can justify a bigger trial, but it should not be presented as an established treatment. Prevention findings also should not be used to claim a drug treats Long COVID that has already developed.
Do Nattokinase, Curcumin, Bromelain or Other Supplements Help Long COVID?
Supplements are among the most frequently discussed options for people with Long COVID. Nattokinase, curcumin and bromelain have attracted interest because of proposed effects on fibrin, inflammation and viral proteins. However, biological plausibility is not the same as proof that a treatment improves symptoms or recovery in humans.
Our evidence review distinguishes four separate questions:
- Does the substance affect a relevant biological pathway in laboratory experiments?
- Has it been shown to affect that pathway in people with Long COVID?
- Have controlled human trials demonstrated meaningful improvements in symptoms or daily functioning?
- Are the benefits sufficiently established to justify the risks and cost?
An intervention can have an interesting mechanism without having demonstrated clinical efficacy. This distinction is particularly important when evaluating supplements marketed as spike-protein detoxification or microclot treatments.
Nattokinase: Fibrinolysis, Microclots and Long COVID
Nattokinase is an enzyme produced during the fermentation of soybeans to make natto, a traditional Japanese food. Laboratory and broader cardiovascular research has investigated its fibrinolytic activity: its ability to act on fibrin, a protein involved in blood clot formation. Researchers have also investigated other proposed anti-inflammatory and antithrombotic effects.
These properties have led to the hypothesis that nattokinase might help address fibrin-related abnormalities proposed in some patients with Long COVID. Other laboratory research has explored its effects on SARS-CoV-2 spike protein.
What does the human Long COVID evidence show?
The 2026 narrative review Candidate treatments for Long COVID: a review of expert and patient-driven priorities included nattokinase among the interventions considered. The review did not identify human studies demonstrating benefit from nattokinase for Long COVID.
A separate 2026 review, Nattokinase: A multifunctional food-derived enzyme for thrombophilia management, examined its biological mechanisms and potential antithrombotic applications. It also highlighted limitations involving clinical evidence, standardization and translation into clinical practice. It was not a trial demonstrating efficacy for Long COVID.
Oxford CEBM assessment: Level 5 for direct Long COVID treatment efficacy; insufficient evidence. This label refers to the mechanistic evidence supporting the proposed treatment, not to the quality of every general nattokinase review.
The absence of demonstrated clinical benefit is not proof that nattokinase could never help a particular subgroup. It does mean that it should not be presented as an established Long COVID treatment, a proven way to remove persistent spike protein, or a validated treatment for presumed microclots.
Safety considerations
Nattokinase may affect fibrin breakdown and clotting pathways. Potential interactions and bleeding risks are important, particularly for people taking anticoagulants or antiplatelet medicines, those with bleeding disorders, and people preparing for surgery. The risks of combining multiple supplements that may influence clotting are not adequately established.
Do not replace prescribed anticoagulation with nattokinase or use it to self-treat a suspected blood clot. Discuss supplements with a qualified clinician or pharmacist, particularly when taking warfarin, apixaban, rivaroxaban, dabigatran, aspirin or clopidogrel.
Curcumin: Anti-Inflammatory Effects and New 2026 Evidence
Curcumin is a bioactive compound found in turmeric (Curcuma longa). It has been studied for anti-inflammatory and antioxidant effects. These properties provide a rationale for research into whether curcumin might help selected Long COVID symptoms. However, laboratory effects do not establish clinical benefit, and different curcumin formulations cannot automatically be treated as equivalent.
What did the 2026 study find?
A study published on 31 July 2026 in Pharmaceuticals investigated quercetin–curcumin co-supplementation in 15 adults with Long COVID. Fourteen participants completed the study. Participants received the combination alongside usual symptomatic care for eight weeks.
The investigators reported improvements from baseline in patient-reported overall symptom burden, fatigue and pain, together with improvement in a measure of physical health-related quality of life.
The critical limitation is study design. It was a single-centre, open-label, single-arm exploratory study without a placebo or usual-care control group. The observed improvements therefore cannot establish that the supplement caused them. Natural symptom fluctuation, expectations, concurrent treatment and regression to the mean may have contributed.
Because quercetin and curcumin were administered together, the individual contribution of curcumin cannot be determined either. The study's authors concluded that adequately powered randomized, placebo-controlled trials are needed before efficacy can be established. The article also discloses that the product manufacturer supplied the study supplement while reporting that the company had no role in study design or conduct.
Oxford CEBM assessment: Level 4 — uncontrolled exploratory study; very low certainty. This is a research signal, not proof that curcumin treats Long COVID.
Safety considerations
Turmeric used as a culinary spice is different from concentrated curcumin supplements. Concentrated products can cause gastrointestinal symptoms and may interact with medicines. Caution is warranted with products that may increase bleeding risk, particularly when combined with anticoagulants or antiplatelet medicines. Some highly bioavailable turmeric formulations have also been associated with rare liver injury.
People taking prescription medication, those with liver or gallbladder conditions, and anyone considering high-dose or enhanced-absorption products should obtain appropriate clinical advice before use.
Bromelain: A Pineapple Enzyme Under Investigation
Bromelain is a mixture of protein-digesting enzymes obtained from pineapple. Research has investigated its possible anti-inflammatory and other biological effects. Laboratory findings have contributed to interest in bromelain as a possible component of supplement combinations intended to address inflammation, fibrin-related abnormalities or viral proteins.
However, evidence of activity in a laboratory experiment does not show that an oral supplement produces the same effect inside the human body. It also does not establish that bromelain improves fatigue, brain fog, post-exertional malaise or other Long COVID outcomes.
Has bromelain been shown to treat Long COVID?
The 2023 article proposing a nattokinase–bromelain–curcumin "base spike detoxification" protocol was a proposed therapeutic approach, not a randomized clinical trial demonstrating efficacy. Its authors explicitly called for large, prospective, randomized, double-blind, placebo-controlled trials to establish the regimen's risks and benefits.
The 2026 narrative review of candidate Long COVID treatments did not identify human studies demonstrating benefit from nattokinase; this should not be misrepresented as direct proof that bromelain has been tested and found ineffective. Rather, the proposed bromelain treatment remains without adequate direct clinical evidence establishing efficacy for Long COVID.
Oxford CEBM assessment: Level 5 for the proposed Long COVID treatment mechanism; insufficient evidence. Bromelain is not an established antiviral or Long COVID treatment.
Sources: Hulscher and colleagues. Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination. 2023. and US National Center for Complementary and Integrative Health: Bromelain.
Safety considerations
Oral bromelain may cause gastrointestinal symptoms or allergic reactions. Potential medication interactions deserve particular attention in people taking medicines that affect clotting. A healthcare professional or pharmacist should review its use alongside prescription drugs and other supplements.
The Nattokinase–Bromelain–Curcumin Combination: Is the "Spike Detox" Protocol Proven?
A proposed protocol combining nattokinase, bromelain and curcumin was published in 2023 as a potential strategy for post-acute sequelae following COVID-19 infection or vaccination. The proposed mechanisms include protein breakdown, effects on inflammation and effects on fibrin-related pathways.
The protocol has attracted attention because it combines three compounds with different biological activities. But the existence of a proposed protocol does not establish that it removes persistent viral material in humans, eliminates clinically important microclots, reverses Long COVID or improves long-term outcomes.
The original publication itself acknowledged that large, prospective, randomized, double-blind, placebo-controlled trials were needed to determine the regimen's relative risks and benefits. A mechanistic proposal should therefore not be described as a validated treatment protocol.
The term "spike protein detoxification" in this context is the name given to a proposed therapeutic hypothesis. It is not evidence that a clinically validated detoxification process has been demonstrated. Persistent symptoms also do not, on their own, establish persistent spike protein or microclots as the cause.
Oxford CEBM assessment: Level 5 — proposed mechanism and protocol, without confirmatory randomized clinical evidence. The combination should be regarded as experimental rather than recommended routine treatment.
Combining these products may introduce overlapping or uncertain bleeding risks and drug interactions. There is insufficient evidence to establish the safety or efficacy of the combination for Long COVID. Do not self-prescribe it, discontinue prescribed treatment or use it in place of assessment for a suspected blood clot.
Primary source: Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination, 2023.
Low-Dose Naltrexone (LDN)
Low-dose naltrexone is a separate investigational treatment that has attracted interest for fatigue, pain, sleep problems and cognitive symptoms. A systematic review searching through May 2026 identified four small observational before-and-after studies involving 155 participants and no eligible randomized controlled trials.
The studies reported possible benefits, but uncontrolled improvement cannot distinguish a drug effect from natural recovery, placebo responses or changes in other treatments. The review therefore does not establish LDN's efficacy, optimal dose, duration or long-term safety for Long COVID.
LDN remains investigational for this indication. It also has important interactions with opioid medicines and should be considered only with a qualified prescriber.
Source: Effect of low-dose naltrexone for Long COVID: a systematic review and meta-analysis. BMJ Open, 2026.
Korean Red Ginseng and Long COVID
In a 2025 study, a twelve-week trial of 220 recently infected patients randomized to either a standardized Korean red ginseng extract or a placebo; those taking the root reported significantly less chronic fatigue by the end of the study, with the benefit most pronounced in women. Underneath that fatigue improvement, researchers found something that looked like real immune repair: the ratio of two key immune cell types — a marker of how well the immune system has recovered its balance after a viral assault — rose substantially in the treated group, while a population of regulatory immune cells that normally gets depleted after infection collapsed sharply in the placebo group but held steady in those taking the root. In plain terms, the treated patients’ immune systems looked like they were healing on schedule, while the placebo group’s immune systems looked like they were still catching their breath.Other Supplements: Correct Deficiencies, Not Unproven Mechanisms
Vitamin D, vitamin B12, iron and other nutrients may be important when a person has a documented deficiency or another recognized indication for treatment. Correcting a deficiency is different from claiming that supplementation cures Long COVID.
There is no validated supplement combination that reliably reverses Long COVID. Avoid megadoses, expensive bundles marketed as cures, and products whose claims rest only on laboratory mechanisms, testimonials or uncontrolled observations.
The evidence standard remains the same for supplements as for prescription drugs: appropriately controlled human trials, meaningful patient outcomes, adequate follow-up and transparent reporting of adverse effects.
What does the evidence support in 2026, and what remains experimental?
| Status | What it includes | Why |
|---|---|---|
| Supported | Individualized, symptom-focused care; pacing for PESE; evaluation for other conditions | Consistent with CDC and WHO guidance; fatigue improved in specialist-clinic care in STIMULATE-ICP (not a controlled comparison) |
| Promising, unconfirmed | SIM01 synbiotic; physical-activity coaching; metformin or Paxlovid for prevention | Randomized signals, but single-centre, pilot-sized, underpowered or mixed |
| Not supported as general treatment | Extended Paxlovid; short-course metformin or UDCA; 10-session hyperbaric oxygen; routine multi-organ MRI | Negative or null primary endpoints in randomized trials |
| Experimental | Intermittent fasting; bezisterim; viral-persistence, microclot, autoimmunity and dopamine hypotheses; biomarker-guided therapy | Small, unblinded, unreviewed or mechanistic evidence only |
| Insufficient evidence | Nattokinase; low-dose naltrexone | No randomized Long COVID trial found (nattokinase) or none published (LDN) |
A negative randomized trial tests a particular drug, dose, timing, population and outcome; it does not erase a biological hypothesis. Equally, a mechanism, physician recommendation, testimonial or observational association is not equivalent to randomized evidence. The field is moving toward asking which treatment works for which biological or symptom-defined subgroup.
How should you read a Long COVID treatment claim?
Symptoms fluctuate naturally, people try several therapies at once, and improvement can occur without a single cause. A real improvement is not the same as proof that a treatment caused it. Ask:
- Was the study randomized, and was there a placebo or sham control?
- How many people finished, and how many dropped out?
- Was the intervention blinded, and what was the primary endpoint?
- Was the result statistically significant and clinically meaningful?
- Was it replicated, and how durable was the benefit?
- Was the finding a primary or only a secondary outcome?
- What adverse events occurred?
- Does it concern prevention or treatment of established disease?
Evidence ladder: mechanism suggests a hypothesis; observation suggests a signal; a randomized trial estimates a treatment effect; replication across high-quality trials builds confidence.
What should patients do with this evidence?
Current evidence supports an individualized approach rather than a universal protocol. Clinical evaluation usually starts with the symptoms causing the most functional impairment and with excluding other diseases that mimic or accompany Long COVID, which may involve cardiovascular, pulmonary, neurological, autonomic, sleep or metabolic assessment. If you experience PESE, ask for pacing and energy-conservation guidance rather than graded exercise alone. Bring the trial names and sample sizes from this article to your appointment.
How can you use this article with Claude, ChatGPT, Gemini and Perplexity?
AI assistants can help you prepare questions and compare trials, but they can be outdated or wrong and are not a substitute for a clinician. Ask for named trials, sample sizes and links to primary sources, then check them.
| Assistant | Useful for | Example prompt |
|---|---|---|
| Claude | Turning this article into questions for your clinician | "Using only the randomized trials in this article, list the evidence for treating [my main symptom] in established Long COVID, and the questions I should ask my doctor." |
| ChatGPT | Side-by-side comparisons and visit-prep sheets | "Compare the SIM01 trial and the physical-activity coaching pilot: size, endpoint, result, limits and what is still unknown." |
| Gemini | Cross-checking against official guidance | "Does current CDC guidance agree with this article's description of post-exertional symptom exacerbation? Cite the CDC page." |
| Perplexity | Finding newer trials with primary sources | "List Long COVID randomized trials published after October 1, 2026, with design, sample size, primary endpoint and a link to the paper." |
Frequently asked questions about Long COVID treatment
What is the best treatment for Long COVID in 2026?
No treatment has been proven effective for Long COVID in general. Randomized trials support individualized, symptom-focused care, and a few approaches show preliminary signals, including the SIM01 synbiotic and physical-activity coaching. Extended Paxlovid, metformin and short-course hyperbaric oxygen did not beat placebo or sham on their primary endpoints. A clinician should tailor care to your main symptoms and exclude other conditions.
Does Paxlovid work for Long COVID?
Not as a treatment for established Long COVID. In RECOVER-VITAL, 959 adults received 15 or 25 days of nirmatrelvir–ritonavir or placebo, and no benefit appeared in any studied phenotype. Giving Paxlovid during acute COVID showed a possible prevention signal in the small PANORAMIC Norway trial (144 people), but that study stopped early and needs confirmation.
Can metformin prevent or treat Long COVID?
Results differ by timing. For established Long COVID, a 396-person randomized trial found no benefit over placebo. For prevention, COVID-OUT reported 41% lower Long COVID incidence with metformin started during acute COVID, while ACTIV-6 missed its primary endpoint but favored metformin on clinician-diagnosed Long COVID. Metformin for prevention remains unproven.
Is intermittent fasting a proven Long COVID treatment?
No. The only randomized trial was small, unblinded and patient-reported: 58 of 77 starters completed it, and symptom scores fell more during fasting weeks. However, 90% of completers reported at least one flare-up, and two hospitalizations were reported, one before fasting began. Prolonged water fasts can be unsafe for some people, so discuss any fasting plan with a clinician.
Do probiotics help Long COVID?
One standardized synbiotic, SIM01, helped more participants than placebo on fatigue, memory, concentration, digestive symptoms and general unwellness at six months in a 463-person Hong Kong trial. That result applies to that formulation, comes from one centre and awaits replication. It should not be generalized to other probiotics or fermented foods.
Does hyperbaric oxygen work for Long COVID?
Evidence is insufficient for routine use. In the sham-controlled HOT-LoCO trial, 10 sessions in 80 people did not outperform sham treatment on the primary endpoints. An earlier trial using a different protocol reported benefits, so effects may depend on protocol and patient selection, and larger confirmatory trials are needed.
Does nattokinase work for Long COVID?
October 2026 literature check found no completed randomized trial testing nattokinase for Long COVID symptoms. Laboratory and mechanistic findings are hypothesis-generating only. Nattokinase has fibrinolytic activity, so people taking blood thinners or facing surgery should speak with a clinician first.
Is exercise safe for people with Long COVID?
It depends on whether you have post-exertional symptom exacerbation (PESE), where activity triggers delayed symptom worsening. A 50-person pilot found symptom-guided activity coaching feasible and safe, but exercise should be individualized, paced and monitored. Pushing through symptoms can backfire; a clinician or rehabilitation specialist familiar with Long COVID can help set limits.
Does curcumin help Long COVID?
A 2026 exploratory study involving 15 adults reported improvements after eight weeks of quercetin–curcumin supplementation, but it had no control group. The individual effect of curcumin could not be separated from quercetin or other influences. Randomized, placebo-controlled trials are needed before efficacy can be established.
Does bromelain help Long COVID?
Bromelain has biological properties that have prompted research interest, but it is not an established Long COVID treatment. Its inclusion in a proposed nattokinase–bromelain–curcumin protocol does not demonstrate efficacy. Adequate controlled clinical trials are needed.
Is the nattokinase–bromelain–curcumin spike detox protocol proven?
The combination was proposed in a 2023 article based on biological hypotheses. Confirmatory randomized controlled trials have not established that it removes persistent spike protein, treats presumed microclots or improves Long COVID outcomes. The combination's safety for this purpose is also insufficiently established.
Sources and further reading
- Baden L, Shah N, Liu S, et al. Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition (RECOVER-VITAL). Lancet Infect Dis 2026. DOI
- Geng LN, et al. Nirmatrelvir–ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection (STOP-PASC). JAMA Intern Med 2024;184:1024. PubMed
- PAX LC: nirmatrelvir–ritonavir vs placebo–ritonavir in long COVID. Lancet Infect Dis 2025. Lancet
- Oppegaard et al. Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway). Lancet Infect Dis 2026. PubMed
- Lau RI, et al. A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY). Lancet Infect Dis 2024;24(3):256–265. PMID 38071990. PubMed
- Bunker T, et al. Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial. Sci Rep 2025;15:27563. Sci Rep
- Lim SY, et al. Neither metformin nor ursodeoxycholic acid effectively treats postacute sequelae of COVID-19. Ann Intern Med 2026. PubMed
- Bramante CT, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT). Lancet Infect Dis 2023;23:1119–1129. PubMed
- ACTIV-6 Study Group. Metformin on the presence of COVID-19 symptoms over 6 months: the ACTIV-6 randomized clinical trial. PubMed
- STIMULATE-ICP: integrated care pathway in individuals with Long COVID, a cluster-randomized phase 3 trial. Nat Med 2026. Nature Medicine
- Kjellberg A, et al. Ten sessions of hyperbaric oxygen versus sham treatment in patients with long covid (HOT-LoCO). BMJ Open 2025;15(4):e094386. BMJ Open
- Hadanny A, et al. Long term outcomes of hyperbaric oxygen therapy in post covid condition: longitudinal follow-up of a randomized controlled trial. Sci Rep 2024;14:3604. DOI
- Diciolla NS, et al. Physical activity coaching programme for people with Long COVID: a pilot randomised clinical trial. Sci Rep 2026;16:14820. Sci Rep
- Tamariz L, et al. Systematic review of randomized clinical trials for the treatment of long COVID syndrome. J Community Hosp Intern Med Perspect 2026;16(4). PMC
- Byambasuren O, et al. Effect of low-dose naltrexone for long covid: a systematic review and meta-analysis. BMJ Open 2026;16(7):e111253. BMJ Open
- Science Feedback. No scientific evidence for the claim that nattokinase can treat long COVID. Science Feedback
- BioVie. Topline results from the phase 2 ADDRESS-LC trial of bezisterim. Press release, September 15, 2026 (not peer reviewed). GlobeNewswire
- CDC. Long COVID clinical guidance. CDC
- World Health Organization. Post COVID-19 condition resources. WHO
- Baptista SN, Atkins T, Chakraborty S, et al. Candidate treatments for Long COVID: a narrative review of expert and patient-driven priorities. Frontiers in Medicine. 2026;13:1734600. DOI: 10.3389/fmed.2026.1734600.
- Khan A, Rabbani F, Mumtaz SU, et al. Potential Adjunctive Effects of Quercetin–Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study. Pharmaceuticals. 2026;19(8):1202. DOI: 10.3390/ph19081202.
- Hulscher N, Alexander PE, Amerling R, et al. Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination. 2023. Proposed nattokinase–bromelain–curcumin protocol; calls for large randomized controlled trials. Read full article.
- Ma Y, Jia H, Fan J, et al. Nattokinase: A multifunctional food-derived enzyme for thrombophilia management. Life Sciences. 2026;397:124439. DOI: 10.1016/j.lfs.2026.124439.
- US National Center for Complementary and Integrative Health. Bromelain: overview of evidence and safety. Read official guidance.
- Hulscher N, et al. Case Report: Resolution of Refractory COVID-19 Vaccine-Induced Myopericarditis with Adjunctive Rapamycin. European Society of Medicine. 2024. https://doi.org/10.18103/mra.v12i11.6099.
Related OneDayMD pages (practitioner-protocol and mechanistic content; lower-tier evidence than the randomized trials above): Post-COVID and post-vaccine spike protein recovery guide · Peter McCullough spike protein detox protocol · How to measure spike protein antibodies · I-Recover protocol and McCullough Base Spike Detox guide · Nutraceuticals and Long COVID
Last updated: October 2026 · Topics:
long covid
·
metformin
·
probiotics
·
fasting
 |
| Check Price on The Wellness Company |
Comments
Post a Comment